Cue Biopharma, Inc.: management transactions · United States · SEC (Form 4)

About Cue Biopharma, Inc.

Cue Biopharma, Inc. is a U.S.-listed clinical-stage biopharmaceutical company traded on the Nasdaq in the United States, focused on developing therapeutic biologics that selectively engage and modulate disease-specific T cells. From an investor’s perspective, the company sits squarely in the healthcare/pharma segment, with a high-risk, high-upside profile typical of platform-driven biotech names. It was founded in December 2014 and built around research originating from the laboratory of Dr. Steven Almo at Albert Einstein College of Medicine. A foundational licensing agreement with Einstein, signed in January 2015, granted key patent rights supporting Cue’s core technology base. The company’s corporate headquarters are in Boston, Massachusetts. Cue’s central asset is its proprietary Immuno-STAT® platform (Selective Targeting and Alteration of T cells), designed to target disease-relevant T cells with greater precision than conventional broad immune-modulating approaches. The strategic goal is to create injectable biologics that can enhance efficacy while limiting off-target immune effects. Over time, Cue has developed a pipeline spanning oncology and immune-mediated disease, but the company’s messaging and recent execution have increasingly emphasized autoimmune and inflammatory disorders as the main value-creation opportunity. The most important development in 2025-2026 is CUE-401, which management describes as the company’s lead autoimmune asset and a program being advanced toward IND readiness. This is an important signal for investors because it indicates a pipeline re-centering around a differentiated lead candidate rather than a broad early-stage portfolio. Cue also expanded its strategic options through partnerships: it announced a collaboration and license agreement with ImmunoScape aimed at a solid-tumor cell therapy approach, and it entered into an exclusive license agreement with Ascendant Health Sciences for a dual-mechanism anti-IgE antibody. These deals suggest a willingness to monetize technology, diversify risk, and support development through external capital and collaborations. Commercially, Cue remains a pre-revenue or limited-revenue biotech in the traditional sense, with collaboration revenue playing a meaningful role in recent financial reporting. The company continues to rely on external financing to fund R&D and operations, which is consistent with a development-stage biotech that has not yet reached product commercialization. Competitively, Cue is a niche player relative to large multinational immunology and oncology companies. Its potential advantage lies in the uniqueness of the Immuno-STAT platform and the possibility of generating highly targeted therapies with improved tolerability. For international equity investors, CUE on the Nasdaq in the United States is best viewed as a speculative clinical biotech story driven by pipeline execution, partnership optionality, and upcoming regulatory milestones.